Navigation Links
Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Date:1/7/2008

TAMPA, Fla., Jan. 7 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer.

Most recently, Dr. Keeffe served as Professor of Medicine, Chief of Hepatology and Co-Director of the Liver Transplant Program at Stanford University Medical Center. He is a past-president of the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, and served as chair of the Subspecialty Board on Gastroenterology for the American Board of Internal Medicine. He is a Master of the American College of Physicians and a Fellow of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American College of Gastroenterology, and the Royal College of Physicians of Ireland.

"Romark's drug discovery research and ongoing clinical development programs offer the promise of new drugs that could change paradigms for treating viral hepatitis," said Dr. Keeffe. "I am excited to have the opportunity to contribute to the advancement of new therapies in this field."

Dr. Keeffe's research interests include antiviral therapy of chronic hepatitis B and C, use of hepatitis vaccines, and liver transplant selection criteria and outcomes. Throughout his career, he has been an active clinical investigator, with a major focus on novel treatment of chronic viral hepatitis and has published more than 500 papers, book chapters and miscellaneous publications. He lectures widely at national and international scientific meetings, and postgraduate courses.

"We are pleased that Dr. Keeffe has chosen to join our Company," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "His expertise in the fields of hepatology and gastroenterology will be invaluable as we advance the development of nitazoxanide and other thiazolides for treating viral hepatitis and other digestive diseases."

About Romark Laboratories

Romark Laboratories, L.C. (http://www.romark.com) is a biotechnology company committed to the discovery and development of innovative new small molecules for treating infectious diseases, cancers, and autoimmune diseases. The Company is developing nitazoxanide for treating chronic hepatitis C and is developing other new thiazolides for treating viral diseases including chronic hepatitis B and C, and influenza.


'/>"/>
SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
5. ARUP Laboratories Releases ARUP Consult(R) 2.0
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. Stiefel Laboratories Appoints Two New Members to Board of Directors
8. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH ... Drug Evaluation Staff has joined the company as an Expert Consultant. , In ...
(Date:2/22/2017)... and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 /PRNewswire/ ... today announced its financial results for the fourth ... "Our annual 2016 financial results reflect continued growth ... exceeded $700 million," said Martine Rothblatt, Ph.D., United ... results strengthen our ability to develop and advance ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS ... digital health applications, announced a partnership with Redox, a leader in cloud-based healthcare ... many clinical systems while keeping data secure in the cloud. , The digital ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics ... has joined its executive team to lead the development and commercialization of its ... help improve the diagnosis and treatment of cancer. The CIDT addresses the need ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):